

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 10, 2026**

**Aquestive Therapeutics, Inc.**  
(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**001-38599**  
(Commission File Number)

**82-3827296**  
(I.R.S. Employer Identification No.)

**30 Technology Drive  
Warren, NJ 07059  
(908) 941-1900**  
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	AQST	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

(a) Aquestive Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2026.

(b) The final voting on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

(1) The following director nominees were elected to serve as Class II members of the Board of Directors, to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified:

Nominee	Votes For	Votes Against	Votes Abstaining	Broker Non-Votes
Gregory B. Brown, M.D.	41,373,033	—	1,222,711	37,465,582
John S. Cochran	36,914,899	—	5,680,845	
Abigail L. Jenkins	39,094,166	—	3,501,578	

(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.

Votes For	Votes Against	Votes Abstaining	Broker Non-Votes
37,798,609	3,192,381	1,604,754	37,465,582

(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.

Votes For	Votes Against	Votes Abstaining
78,804,323	910,690	346,313

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit Number	Description
104	Cover Page Interaction Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: **June 10, 2026**

Aquestive Therapeutics, Inc.

By: /s/ A. Ernest Toth, Jr

Name: A. Ernest Toth, Jr.

Title: Chief Financial Officer